奥妥珠单抗在类风湿关节炎与系统性红斑狼疮患者样本中诱导优于利妥昔单抗的B细胞细胞毒性
本研究在RA和SLE患者样本的体外全血试验中比较利妥昔单抗(RTX)与新一代糖工程化II型抗CD20单抗奥妥珠单抗(OBZ)的B细胞细胞毒性。OBZ诱导B细胞细胞毒性至少比RTX强2倍,且对与RTX治疗后临床反应不佳相关的naïve和 switched记忆B细胞亚群更有效。机制上RTX补体依赖细胞毒性更强,而OBZ的Fcγ受体介导效应和直接细胞死亡更强,为RTX抵抗提供机制基础并支持OBZ作为替代B细胞清除剂。
要点
- OBZ在RA和SLE患者全血体外试验中诱导B细胞细胞毒性至少比RTX强2倍。
- OBZ对naïve和switched记忆B细胞亚群更有效,该亚群高频与RTX后临床反应不佳相关。
- RTX补体依赖细胞毒性更强,OBZ的Fcγ受体介导效应和直接细胞死亡更强。
核心结论
- OBZ在RA和SLE患者样本中诱导的B细胞细胞毒性至少为RTX的2倍。
- OBZ对naïve(IgD+CD27-)和switched(IgD-CD27+)记忆B细胞亚群更有效。
- 数据为RTX诱导B细胞清除抵抗提供机制基础,并支持在RA和SLE中考虑OBZ作为替代B细胞清除剂。
研究设计与样本
- 在RA和SLE患者样本中进行一系列体外全血试验,比较RTX与OBZ的B细胞细胞毒性。
主要发现
- OBZ在体外全血试验中诱导B细胞细胞毒性至少比RTX强2倍。
- RTX诱导的补体依赖细胞毒性比OBZ更强。
- OBZ更有效引发Fcγ受体介导的效应机制,包括NK细胞和中性粒细胞活化。
- OBZ与Fcγ受体相互作用更强,且结合CD20后仍留在细胞表面,而RTX被内化。
- OBZ诱导直接细胞死亡更有效,对全部CD19+B细胞及naïve和switched记忆B细胞均如此。
临床怎么用
- 对于标准剂量RTX治疗后B细胞清除不佳或临床反应不良的RA和SLE患者,可考虑OBZ作为替代B细胞清除剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: A proportion of RA and SLE patients treated with standard doses of rituximab (RTX) display inefficient B cell deletion and poor clinical responses that can be augmented by delivering higher doses, indicating that standard-dose RTX is a sub-optimal therapy in these patients. This study aimed to investigate whether better responses could be achieved with mechanistically different anti-CD20 mAbs. METHODS: We compared RTX with obinutuzumab (OBZ), a new-generation, glycoengineered type II anti-CD20 mAb, in a series of in vitro assays measuring B cell cytotoxicity in RA and SLE patient samples. RESULTS: We found that OBZ was at least 2-fold more efficient than RTX at inducing B-cell cytotoxicity in in vitro whole blood assays. Dissecting this difference, we found that RTX elicited more potent complement-dependent cellular cytotoxicity than OBZ. In contrast, OBZ was more effective at evoking Fc gamma receptor-mediated effector mechanisms, including activation of NK cells and neutrophils, probably due to stronger interaction with Fc gamma receptors and the ability of OBZ to remain at the cell surface following CD20 engagement, whereas RTX became internalized. OBZ was also more efficient at inducing direct cell death. This was true for all CD19 + B cells as a whole and in naïve (IgD + CD27 - ) and switched (IgD - CD27 + ) memory B cells specifically, a higher frequency of which is associated with poor clinical response after RTX. CONCLUSION: Taken together, these data provide a mechanistic basis for resistance to rituximab-induced B-cell depletion, and for considering obinutuzumab as an alternative B-cell depleting agent in RA and SLE.
引用
- Reddy V, Klein C, Isenberg DA, et al. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology (Oxford). 2017. PMID: 28407142. doi:10.1093/rheumatology/kex067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。